Skip to main content

Advertisement

SpringerLink
Log in

Should antiretroviral therapy be started earlier?

  • Published:
Current HIV/AIDS Reports Aims and scope Submit manuscript

Abstract

Current treatment guidelines recommend that antiretroviral therapy be deferred until the CD4 count has fallen into the 200 to 350 cells/mm3 range. However, treatment has become simpler, less toxic, and more forgiving of missed doses. Longer-term follow-up data from clinical cohorts are now showing better outcomes when therapy is started at higher CD4 cell counts. Therapy initiated early has better virologic and immunologic responses, is better tolerated, and is cost-effective. Recent developments and clinical data support a return to earlier initiation of therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Gulick RM, Mellors JW, Havlir D, et al.: Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997, 337:734–739.

    Article  PubMed  CAS  Google Scholar 

  2. Perlson AS, Essunger P, Cao Y, et al.: Decay characteristics of HIV-1-infected compartments during combination therapy. Nature 1997, 387:188–191.

    Article  Google Scholar 

  3. Finzi D, Hermankova M, Pierson T, et al.: Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 1997, 278:1295–1300.

    Article  PubMed  CAS  Google Scholar 

  4. Wong JK, Hezarch M, Gunthard HF, et al.: Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 1997, 278:1291–1295.

    Article  PubMed  CAS  Google Scholar 

  5. Chun T-W, Engel D, Berrey MM, et al.: Early establishment of a pool of latently infected, resting CD4+T cells during primary HIV-1 infection. Proc Natl Acad Sci USA 1998, 95:8869–8873.

    Article  PubMed  CAS  Google Scholar 

  6. Egger M, May M, Chene G, et al.: Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 2002, 360:119–129.

    Article  PubMed  Google Scholar 

  7. Sethi AK, Celentano DD, Gange SJ, et al.: Association between adherence with antiretroviral therapy and HIV drug resistance. Clin Infect Dis 2003, 37:1112–1118.

    Article  PubMed  Google Scholar 

  8. Carr A, Samaras K, Burton S, et al.: A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998, 12:F51–58.

    Article  PubMed  CAS  Google Scholar 

  9. Holmberg SD, Moorman AC, Williamson JC, et al.: Protease inhibitors and cardiovascular outcomes in patients with HIV-1. Lancet 2002, 360:1747–1748.

    Article  PubMed  CAS  Google Scholar 

  10. Department of Health and Human Services: Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. October 10, 2006. http://aidsinfo.nih.gov. Accessed January 14, 2007.

  11. Hammer SM, Saag MS, Schechter M, et al.: Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA Panel. JAMA 2006, 206:827–843.

    Article  Google Scholar 

  12. Gallant JE, DeJesus E, Arribas JR, et al.: Tenofovir, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med 2006, 354:251–260.

    Article  PubMed  CAS  Google Scholar 

  13. Gallant JE, Staszewski S, Pozniak AL, et al.: Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naïve patients: a randomized trial. JAMA 2004, 292:191–201.

    Article  PubMed  CAS  Google Scholar 

  14. Friis-Moller N, Reiss P, El-Sadr W, et al.: Exposure to PI and NNRTI and risk of myocardial infarction: results from the D:A:D study [abstract 144]. Paper presented at the 13th Conference on Retroviruses and Opportunistic Infections. Denver, CO; February 5–8, 2006.

  15. Lucas GM, Chaisson RE, Moore RD: Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions. Ann Intern Med 1999, 131:81–87.

    PubMed  CAS  Google Scholar 

  16. Lichtenstein KA, Armon C, Buchacz K, et al.: Early, uninterrupted ART is associated with improved outcome and fewer toxicities in the HIV Outpatient Study (HOPS) [abstract 769]. Paper presented at the 13th Conference on Retroviruses and Opportunistic Infections. Denver, CO; February 5–8, 2006.

  17. Paterson DL, Swindells S, Mohr J, et al.: Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000, 133:21–30.

    PubMed  CAS  Google Scholar 

  18. Walmsley S, Bernstein B, King M, et al.: Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl J Med 2002, 346:2039–2046.

    Article  PubMed  CAS  Google Scholar 

  19. Bangsberg D: Less than 95% adherence to nonnucleoside reverse-transcriptase inhibitor therapy can lead to viral suppression. Clin Infect Dis 2006, 43:939–941.

    Article  PubMed  CAS  Google Scholar 

  20. Kempf DJ, King MS, Bernstein B, et al.: Incidence of resistance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine. J Infect Dis 2004, 189:51–60.

    Article  PubMed  CAS  Google Scholar 

  21. Gathe JC Jr, Ive P, Wood R, et al.: SOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir/ritonavir versus twice-daily nelfinavir in naïve HIV-1-infected patients. AIDS 2004, 18:1529–1537.

    Article  PubMed  CAS  Google Scholar 

  22. Bartlett JA, Fath MJ, Demasi R, et al.: An updated systematic overview of triple combination therapy in antiretroviralnaive HIV-infected adults. AIDS 2006, 20:2051–2064.

    Article  PubMed  CAS  Google Scholar 

  23. Lampe FC, Gatell JM, Staszewski S, et al.: Changes over time in risk of initial virological failure of combination antiretroviral therapy: a multicohort analysis, 1996 to 2002. Arch Intern Med 2006, 166:521–528.

    Article  PubMed  CAS  Google Scholar 

  24. Moore RD, Keruly JC, Gebo KA, Lucas GM: An improvement in virologic response to highly active antiretroviral therapy in clinical practice from 1996 through 2002. J Acquire Immune Defic Syndr 2005, 39:195–198.

    Google Scholar 

  25. Opravil M, Ledergerber B, Furrer H, et al.: Clinical efficacy of early initiation of HAART in patients with asymptomatic HIV infection and CD4 cell count > 350 × 10(6)/1. AIDS 2002, 16:1371–1381.

    Article  PubMed  CAS  Google Scholar 

  26. Sterling TR, Chaisson RE, Keruly J, Moore RD: Improved outcomes with earlier initiation of highly active antiretroviral therapy among human immunodeficiency virus-infected patients who achieve durable virologic suppression: longer follow-up of an observational cohort study. J Infect Dis 2003, 188:1659–1665.

    Article  PubMed  Google Scholar 

  27. Wang C, Vlahov D, Galai N, et al.: Mortality in HIV-seropositive versus-seronegative persons in the era of highly active antiretroviral therapy: implications for when to initiate therapy. J Infect Dis 2004, 190:1046–1054.

    Article  PubMed  Google Scholar 

  28. Sterne J, May M, Costagliola D, et al.: Estimating the optimum CD4 threshold for starting HAART in ART-naïve HIV-infected individuals [abstract 525]. Paper presented at the 13th Conference on Retroviruses and Opportunistic Infections. Denver, CO; February 5–8, 2006.

  29. Chaisson RC, Moore RD: Natural history of opportunistic disease in an HIV-infected urban clinical cohort. Ann Intern Med 1996, 124:633–642.

    PubMed  Google Scholar 

  30. Mellors JW, Munoz A, Giorgi JV, et al.: Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 1997, 126:946–954.

    PubMed  CAS  Google Scholar 

  31. Phillips A, CASCADE Collaboration: Short-term risk of AIDS according to current CD4 cell count and viral load in antiretroviral drug-naive individuals and those treated in the monotherapy era. AIDS 2004, 18:51–58.

    Article  PubMed  CAS  Google Scholar 

  32. Strategies for Management of Antiretroviral Therapy (SMART) Study Group: CD4-guided antiretroviral treatment interruption: primary results of the SMART study. N Engl J Med 2006, 355:2283–2296.

    Article  Google Scholar 

  33. Palella FJ Jr, Knoll MD, Chmiel JS, et al.: Survival benefit of initiating antiretroviral therapy in HIV-infected persons in different CD4+ cell strata. Ann Intern Med 2003, 138:620–626.

    PubMed  Google Scholar 

  34. Plana M, Garcia F, Gallart T, et al.: Immunological benefits of antiretroviral therapy in very early stages of asymptomatic chronic HIV-1 infection. AIDS 2000, 14:1921–1933.

    Article  PubMed  CAS  Google Scholar 

  35. Appay V, Boutboul F, Autran B: The HIV infection and immune activation: “to fight and burn”. Curr Infect Dis Rep 2005, 7:473–479.

    Article  PubMed  Google Scholar 

  36. Gras L, Van Sighem A, Fraser C, et al.: Predictors for changes in CD4 cell count 7 years after starting HAART [abstract 530]. Paper presented at the 13th Conference on Retroviruses and Opportunistic Infections. Denver, CO; February 5–8, 2006.

  37. Moore RD, Keruly JC: CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression. Clin Infect Dis 2007, 44:441–446.

    Article  PubMed  Google Scholar 

  38. King M, Da Silva BA, McMillan F, et al.: When does the CD4 cell count plateau? Evidence from subjects treated with a lopinavir/ritonavir-based regimen for up to 7 years [abstract H-1401]. Paper presented at the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA; September 27–30, 2006.

  39. Quinn TC, Wawer MJ, Sewankambo N, et al.: Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med 2000, 342:921–929.

    Article  PubMed  CAS  Google Scholar 

  40. Porco TC, Martin JN, Page-Shafer KA, et al.: Decline in HIV infectivity following the introduction of highly active antiretroviral therapy. AIDS 2004, 18:81–88.

    Article  PubMed  Google Scholar 

  41. Tovanabutra S, Robinson V, Wongtrakul J, et al.: Male viral load and heterosexual transmission of HIV-1 subtype E in northern Thailand. J Acquir Immune Defic Syndr 2002, 29:275–283.

    PubMed  Google Scholar 

  42. Gulick R, Su Z, Flexner C, et al.: ACTG 5211: phase II study of the safety and efficacy of vicriviroc in HIV-infected treatment-experienced subjects [abstract THLB0217]. Paper presented at the XVI International AIDS Conference. Toronto, Canada; August 13–18, 2006.

  43. Koot M, Keet IP, Vos AH, et al.: Prognostic value of HIV-1 syncytium-inducing phenotype for rate of CD4+ cell depletion and progression to AIDS. Ann Intern Med 1993, 118:681–688.

    PubMed  CAS  Google Scholar 

  44. Moyle GJ, Wildfire A, Mandalia S, et al.: Epidemiology and predictive factors for chemokine receptor use in HIV-1 infection. J Infect Dis 2005, 191:866–872.

    Article  PubMed  Google Scholar 

  45. Kahn JG, Haile B, Kates J, Chang S: Health and federal budgetary effects of increasing access to antiretroviral medications for HIV by expanding Medicaid. Am J Public Health 2001, 91:1464–1473.

    Article  PubMed  CAS  Google Scholar 

  46. Chen RY, Accortt NA, Westfall AO, et al.: Distribution of health care expenditures for HIV-infected patients. Clin Infect Dis 2006, 42:1003–1010.

    Article  PubMed  CAS  Google Scholar 

  47. Schackman BR, Freedberg KA, Weinstein MC, et al.: Cost-effective implications of the timing of antiretroviral therapy in HIV-infected adults. Arch Intern Med 2002, 162:2478–2486.

    Article  PubMed  CAS  Google Scholar 

  48. Mauskopf J, Kitahata M, Kauf T, et al.: HIV antiretroviral treatment: early versus later. J Acquir Immune Defic Syndr 2005, 39:562–569.

    PubMed  CAS  Google Scholar 

  49. Puoti M, Bonacini M, Spinetti A, et al.: Liver fibrosis is related to CD4 depletion in patients coinfected with hepatitis C virus and human immunodeficiency virus. J Infect Dis 2001, 183:134–137.

    Article  PubMed  CAS  Google Scholar 

  50. Graham CS, Baden LR, Yu E, et al.: Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect Dis 2001, 33:562–569.

    Article  PubMed  CAS  Google Scholar 

  51. Soto B, Sanchez-Quijano A, Rodrigo L, et al.: Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis. J Hepatol 1997, 26:1–5.

    Article  PubMed  CAS  Google Scholar 

  52. Mehta SH, Lucas GM, Mirel LB, et al.: Limited effectiveness of antiviral treatment for hepatitis C in an urban HIV clinic. AIDS 2006, 20:2361–2369.

    Article  PubMed  Google Scholar 

  53. Shafran SD: Early initiation of antiretroviral therapy: the current best way to reduce liver-related deaths in HIV/hepatic C virus-coinfected patients. J Acquir Immune Defic Syndr 2007, In press.

  54. Perinatal HIV Guidelines Working Group: Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV-1 transmission in the United States. October 12, 2006. http://aidsinfo.nih.gov. Accessed January 14, 2007.

  55. Daniel C, Moh R, Minga A, et al.: CD4-guided structured antiretroviral treatment interruption strategy in HIV-infected adults in west Africa (Trivacan ANRS 1269 trial): a randomised trial. Lancet 2006, 367:1981–1989.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Infectious Diseases, Johns Hopkins University School of Medicine, 1830 Fast Monument Street, Room 443, Baltimore, MD, 21205, USA

    Joel E. Gallant MD, MPH

Authors
  1. Joel E. Gallant MD, MPH
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Joel E. Gallant MD, MPH.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gallant, J.E. Should antiretroviral therapy be started earlier?. Curr HIV/AIDS Rep 4, 53–59 (2007). https://doi.org/10.1007/s11904-007-0008-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11904-007-0008-7

Keywords

Search

Navigation